2. Signalwege
  3. Metabolic Enzyme/Protease
  4. HMG-CoA Reductase (HMGCR)
  5. HMG-CoA Reductase (HMGCR) Inhibitor

HMG-CoA Reductase (HMGCR) Inhibitor

HMG-CoA Reductase (HMGCR) Inhibitors (136):

Art. -Nr. Produktname Wirkung Reinheit
  • HY-14664AS
    Fluvastatin-d6 sodium
    		Inhibitor 98.06%
    Fluvastatin-d6 (sodium) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.
  • HY-121795
    Pravastatin lactone
    		Inhibitor 99.20%
    Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis.
  • HY-110231
    Simvastatin-d6
    		Inhibitor 99.6%
    Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
  • HY-N2924
    β-Amyrin palmitate
    		Inhibitor ≥98.0%
    β-Amyrin palmitate shows HMG-CoA reductase inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.
  • HY-W414823
    24,25-Epoxycholesterol
    		Inhibitor 99.80%
    24,25-Epoxycholesterol is an oxysterol agonist of the liver X receptor that can inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) in liver cells. 24,25-Epoxycholesterol regulates cholesterol metabolism in the liver.
  • HY-17379R
    Atorvastatin hemicalcium salt (Standard)
    		Inhibitor
    Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
  • HY-14664CS
    (3S,5R)-Fluvastatin-d6 sodium
    		Inhibitor 98.0%
    (3S,5R)-Fluvastatin-d6 (sodium)?is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-17504AS1
    Rosuvastatin-d6
    		Inhibitor
    Rosuvastatin-d6 (ZD 4522-d6) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-B0589E
    Atorvastatin hemicalcium trihydrate
    		Inhibitor 99.70%
    Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
  • HY-B0589S1
    Atorvastatin-d5 sodium
    		Inhibitor 99.01%
    Atorvastatin-d5 (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
  • HY-108744
    Pitavastatin magnesium
    		Inhibitor 99.76%
    Pitavastatin magnesium is an orally active HMG-CoA Reductase inhibitor. Pitavastatin magnesium lowers total cholesterol and low-density lipoprotein cholesterol in a hyperlipidemic rat model. Pitavastatin magnesium can be used in research on cardiovascular and cerebrovascular diseases such as hyperlipidemia.
  • HY-106281
    Bemfivastatin
    		Inhibitor 99.48%
    Bemfivastatin (PPD 10558) is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin can be used for research of metabolic disease, such as hypercholesterolemia.
  • HY-106281A
    Bemfivastatin hemicalcium
    		Inhibitor 98.00%
    Bemfivastatin (PPD 10558) hemicalcium is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin hemicalcium can be used for research of metabolic disease, such as hypercholesterolemia.
  • HY-122439
    Lovastatin acid
    		Inhibitor
    Lovastatin acid (Mevinolinic acid; MSD803), an active metabolite of Lovastatin (HY-N0504), is a potent competitive HMG-CoA reductase inhibitor with a Ki of 0.6 nM. Lovastatin acid acts as a competitive inhibitor with respect to substrate HMG-CoA, interfering cholesterol synthesis. Lovastatin acid can be used for the research of hypercholesterolemia.
  • HY-N11637
    Ganoderenic acid K
    		Inhibitor 99.64%
    Ganoderenic acid K is a natural product, that can be isolated from fruiting bodies of Ganoderma lucidum. Ganoderenic acid K shows strong inhibitory activity against HMG-CoA reductase (HMGCR) with IC50 of 16.5 μM.
  • HY-B0144AS1
    Pitavastatin-d5 sodium
    		Inhibitor 99.53%
    Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
  • HY-RS06238
    HMGCR Human Pre-designed siRNA Set A
    		Inhibitor

    HMGCR Human Pre-designed siRNA Set A contains three designed siRNAs for HMGCR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-19671
    Apomine
    		Inhibitor 99.67%
    Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer.
  • HY-14664C
    (3S,5R)-Fluvastatin sodium
    		Inhibitor 98.16%
    (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-17504S
    Rosuvastatin-d6 calcium
    		Inhibitor 98.54%
    Rosuvastatin-d6 (calcium) is deuterium labeled Rosuvastatin.